Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients
This study has been completed.
Study NCT00110266   Information provided by Novartis
First Received: May 4, 2005   Last Updated: November 18, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Myelodysplastic Syndrome
Iron Overload
Additional conditions recognized in this trial
Myelodysplastic Syndromes
Preleukemia
Syndrome
More general conditions related to this trial
Bone Marrow Diseases
Disease
Hematologic Diseases
Iron Metabolism Disorders
Metabolic Diseases
Neoplasms
Pathologic Processes
Precancerous Conditions
Interventions listed in this trial
Deferasirox
Additional drug interventions recognized in this trial
Chelating Agents
Iron
More general drug interventions related to this trial
Growth Substances
Iron Chelating Agents
Micronutrients
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Trace Elements
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services